Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib with or without calcipotriol/betamethasone in adults with moderate to severe plaque psoriasis
ChiCTR2400091511Phase 4Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of deucravacitinib, calcipotriol and betamethasone in plaque psoriasis (2 arms), sponsored by Huashan Hospital. Primary endpoints: PASI 75 response rate at week 4 and sPGA 0/1 response rate at week 4. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
deucravacitinibcalcipotriolbetamethasone
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on ChiCTR2400091511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091511.